A Comparison of Lipids and apoB in Asian Indians and Americans
References
- Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 139: e1082–143. DOI: 10.1161/CIR.0000000000000699
- Landmesser U, Chapman MJ, Stock JK, Amarenco P, Belch JJF, Borén J, et al. 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. European Heart Journal. 2018; 39: 1131–43. DOI: 10.1093/eurheartj/ehx549
- Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, De Graaf J, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011; 4: 337–45. DOI: 10.1161/CIRCOUTCOMES.110.959247
- Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013; 45: 1345–52. DOI: 10.1038/ng.2795
- Jørgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjaerg-Hansen A. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. European Heart Journal. 2013; 34: 1826–33. DOI: 10.1093/eurheartj/ehs431
- AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices, Cole TG, Contois JH, Csako G, McConnell JP, Remaley AT, et al. Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: Assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices. Clin Chem. 2013; 59: 752–70. DOI: 10.1373/clinchem.2012.196733
- Langlois MR, Chapman MJ, Cobbaert C, Mora S, Remaley AT, Ros E, et al. Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. Clin Chem. 2018; 64: 1006–33. DOI: 10.1373/clinchem.2018.287037
- Elovson J, Chatterton JE, Bell GT, Schumaker VN, Reuben MA, Puppione DL, et al. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. The Journal of Lipid Research. 1988; 29: 1461–73.
- Sniderman AD, Couture P, Martin SS, DeGraaf J, Lawler PR, Cromwell WC, et al. Hypertriglyceridemia and cardiovascular risk: A cautionary note about metabolic confounding. J Lipid Res. 2018; 59: 1266–75. DOI: 10.1194/jlr.R082271
- Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiol. 2019; 4: 1287–95. DOI: 10.1001/jamacardio.2019.3780
- Borén J, Williams KJ. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Curr Opin Lipidol. 2016; 27: 473–83. DOI: 10.1097/MOL.0000000000000330
- Centers for Disease Control and
Prevention, National Center for Health Statistics Internet.
National Health and Nutrition Examinatory Survery Data
(NHANES). NHANES Questionnaires, Datasets, and Related Documentation
2009–2010 & 2011–2012. https://wwwncdcgov/nchs/nhanes/
2020. Retrieved from:
https://wwwn.cdc.gov/nchs/nhanes/ . Accessed 11 November 2020. - Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material. Clin Chem. 1994; 40: 586–92. DOI: 10.1093/clinchem/40.4.586
- Nair M, Ali MK, Ajay VS, Shivashankar R, Mohan V, Pradeepa R, et al. CARRS Surveillance study: Design and methods to assess burdens from multiple perspectives. BMC Public Health. 2012; 12: 701–12. DOI: 10.1186/1471-2458-12-701
- Prabhakaran D, Jeemon P, Roy A. Cardiovascular Diseases in India: Current Epidemiology and Future Directions. Circulation. 2016; 133: 1605–20. DOI: 10.1161/CIRCULATIONAHA.114.008729
- Robinson JG, Wang S, Jacobson TA. Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. Am J Cardiol. 2012; 110: 1468–76. DOI: 10.1016/j.amjcard.2012.07.007
- Thanassoulis
G,
Williams
K,
Ye
K,
Brook
R,
Couture
P,
Lawler
PR, et al. Relations
of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction
from statin therapy: A meta-analysis of randomized trials.
J Am Heart Assoc. 2014; 3:
e000759–9 . DOI: 10.1161/JAHA.113.000759 - Khan SU, Khan MU, Valavoor S, Khan MS, Okunrintemi V, Mamas MA, et al. Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: Systematic review and meta-analysis of trials. Eur J Prev Cardiol. 2019: 2047487319871733. DOI: 10.1177/2047487319871733
- Sathiyakumar V, Park J, Quispe R, Elshazly MB, Michos ED, Banach M, et al. Impact of Novel LDL-C Assessment on the Utility of Secondary Non-HDL-C and ApoB Targets in Selected Worldwide Dyslipidemia Guidelines. Circulation. 2018: CIRCULATIONAHA.117.032463.
- Sniderman AD, St-Pierre AC, Cantin B, Dagenais GR, Després J-P, Lamarche B. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol. 2003; 91: 1173–7. DOI: 10.1016/S0002-9149(03)00262-5
- Cromwell WC, Otvos JD, Keyes MJ, Pencina MJ, Sullivan L, Vasan RS, et al. LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study – Implications for LDL Management. Journal of Clinical Lipidology. 2007; 1: 583–92. DOI: 10.1016/j.jacl.2007.10.001
- Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. Journal of Clinical Lipidology. 2011; 5: 105–13. DOI: 10.1016/j.jacl.2011.02.001
- Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009; 119: 931–9. DOI: 10.1161/CIRCULATIONAHA.108.816181
- Sniderman AD, Islam S, Yusuf S, McQueen MJ. Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study. Atherosclerosis. 2012; 225: 444–9. DOI: 10.1016/j.atherosclerosis.2012.08.039
- Mora S, Buring JE, Ridker PM. Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation. 2014; 129: 553–61. DOI: 10.1161/CIRCULATIONAHA.113.005873
- Pencina MJ, D’Agostino RB, Zdrojewski T, Williams K, Thanassoulis G, Furberg CD, et al. Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C. Eur J Prev Cardiol. 2015; 22: 2047487315569411–1327. DOI: 10.1177/2047487315569411
- Wilkins JT, Li RC, Sniderman A, Chan C, Lloyd-Jones DM. Discordance Between Apolipoprotein B and LDL-Cholesterol in Young Adults Predicts Coronary Artery Calcification: The CARDIA Study. J Am Coll Cardiol. 2016; 67: 193–201. DOI: 10.1016/j.jacc.2015.10.055
- Lawler PR, Akinkuolie AO, Ridker PM, Sniderman AD, Buring JE, Glynn RJ, et al. Discordance between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in Women. Clin Chem. 2017; 63: 870–9. DOI: 10.1373/clinchem.2016.264515
- Ference BA, Kastelein JJP, Ginsberg HN, Chapman MJ, Nicholls SJ, Ray KK, et al. Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk. JAMA. 2017; 318: 947–56. DOI: 10.1001/jama.2017.11467
- Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, et al. Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease. JAMA. 2019; 321: 364–73. DOI: 10.1001/jama.2018.20045
- Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiol. 2019; 4: 1287–95. DOI: 10.1001/jamacardio.2019.3780
- Würtz P, Havulinna AS, Soininen P, Tynkkynen T, Prieto-Merino D, Tillin T, et al. Metabolite profiling and cardiovascular event risk: A prospective study of 3 population-based cohorts. Circulation. 2015; 131: 774–85. DOI: 10.1161/CIRCULATIONAHA.114.013116
- Ohukainen P, Kuusisto S, Kettunen J, Perola M, Järvelin M-R, Mäkinen V-P, et al. Data-driven multivariate population subgrouping via lipoprotein phenotypes versus apolipoprotein B in the risk assessment of coronary heart disease. Atherosclerosis. 2019; 294: 10–5. DOI: 10.1016/j.atherosclerosis.2019.12.009
- Richardson
TG,
Sanderson
E,
Palmer
TM,
Ala-Korpela
M,
Ference
BA,
Davey
SG, et al.
Evaluating the relationship between circulating lipoprotein
lipids and apolipoproteins with risk of coronary heart disease: A
multivariable Mendelian randomisation analysis.
Rader
DJ, (ed.), PLoS
Med. 2020; 17:
e1003062 . DOI: 10.1371/journal.pmed.1003062 - Zuber V, Gill D, Ala-Korpela M, Langenberg C, Butterworth A, Bottolo L, et al. High-throughput multivariable Mendelian randomization analysis prioritizes apolipoprotein B as key lipid risk factor for coronary artery disease. Int J Epidemiol. 2020. DOI: 10.1101/2020.02.10.20021691
- Hopkins PN, Brinton EA, Nanjee MN. Hyperlipoproteinemia type 3: The forgotten phenotype. Curr Atheroscler Rep. 2014; 16: 440–19. DOI: 10.1007/s11883-014-0440-2
- Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017; 69: 692–711. DOI: 10.1016/j.jacc.2016.11.042
- Afshar
M,
Rong
J,
Zhan
Y,
Chen
HY,
Engert
JC,
Sniderman
AD, et al. Risks of
Incident Cardiovascular Disease Associated With Concomitant Elevations in
Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-The Framingham Heart
Study. J Am Heart Assoc. 2020;
9:
e014711 . DOI: 10.1161/JAHA.119.014711 - Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364: 937–52. DOI: 10.1016/S0140-6736(04)17018-9
- O’Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): A case-control study. Lancet. 2016; 388: 761–75. DOI: 10.1016/S0140-6736(16)30506-2
DOI: https://doi.org/10.5334/gh.882 | Journal eISSN: 2211-8179
Language: English
Submitted on: Jul 18, 2020
Accepted on: Dec 8, 2020
Published on: Jan 20, 2021
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
© 2021 Kavita Singh, George Thanassoulis, Line Dufresne, Albert Nguyen, Ruby Gupta, K M Venkat Narayan, Nikhil Tandon, Allan Sniderman, Dorairaj Prabhakaran, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.